Jana Kopřivová

Jana Kopřivová

Auto-generated profile, based on publicly available information

Jana Kopřivová

National Institute of Mental Health

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2011 in Clinical Neurophysiology
Verified
Journal Article
Closed access
JKJana Kopřivová
Jana Kopřivová
MCMarco Congedo
Marco Congedo
JHJiří Horáček
Jiří Horáček
JPJán Praško
Ján Praško
MRMichal Raszka
Michal Raszka
CHCyril Höschl
Cyril Höschl

1 December 2018 in Sleep Medicine
Verified
Journal Article
Closed access
KWKamila Weissová
Kamila Weissová
JŠJitka Škrabalová
Jitka Škrabalová
KSKateřina Skálová
Kateřina Skálová
KČKateřina Červená
Kateřina Červená
Zdenka BendováZdenka Bendová
Zdenka Bendová
JBJitka Bušková
Jitka Bušková

1 October 2009 in Neuroscience Letters
Verified
Journal Article
Closed access
JKJana Kopřivová
Jana Kopřivová
JHJiří Horáček
Jiří Horáček
JTJaroslav Tintěra
Jaroslav Tintěra
JPJán Praško
Ján Praško
MRMichal Raszka
Michal Raszka
CHCyril Höschl
Cyril Höschl

27 April 2013 in Neuropsychobiology
Verified
Journal Article
Closed access
PDF file
JKJana Kopřivová
Jana Kopřivová
MCMarco Congedo
Marco Congedo
MRMichal Raszka
Michal Raszka
JPJán Praško
Ján Praško
MBMartin Brunovsky
Martin Brunovsky
JHJiří Horáček
Jiří Horáček
Aims: The goal of this study was to assess the effect of independent component neurofeedback (NFB) on EEG and clinical symptoms in patients with obsessive-compulsive disorder (OCD). Subsequently, we explored predictors of treatment response and EEG correlates of clinical symptoms. Methods: In a randomized, double-blind, parallel design, 20 inpatients with OCD underwent 25 sessions of NFB or sham feedback (SFB). NFB aimed at reducing EEG activity in an independent component previously reported abnormal in this diagnosis. Resting-state EEG recorded before and after the treatment was analyzed to assess its posttreatment changes, relationships with clinical symptoms and treatment response. Results: Overall, clinical improvement in OCD patients was not accompanied by EEG change as assessed by standardized low-resolution electromagnetic tomography and normative independent component analysis. Pre- to posttreatment comparison of the trained component and frequency did not yield significant results; however, in the NFB group, the nominal values at the downtrained frequency were lower after treatment. The NFB group showed significantly higher percentage reduction of compulsions compared to the SFB group (p = 0.015). Pretreatment higher amount of delta (1-6 Hz) and low alpha oscillations as well as a lower amount of high beta activity predicted a worse treatment outcome. Source localization of these delta and high beta oscillations corresponded with previous EEG resting-state findings in OCD patients compared to healthy controls. Conclusion: Independent component NFB in OCD proved useful in percentage improvement of compulsions. Based on our correlation analyses, we hypothesize that we targeted a network related to treatment resistance.

22 November 2019 in Chronobiology International
Verified
Journal Article
Closed access
KJKarolina Janků
Karolina Janků
MŠMichal Šmotek
Michal Šmotek
EFEva Fárková
Eva Fárková
JKJana Kopřivová
Jana Kopřivová
The objective of the present study was to assess the effect of combining CBT-I with wearing blue-light blocking glasses 90 min prior to bedtime on subjective and objective sleep parameters and daily symptoms (anxiety, depression, hyperarousal). Thirty patients (mean age 48.1 ± 16.13 years, range 21–71, 15 men/15 women) completed a CBT-I group therapy program, with groups randomly assigned to either “active” (blue-light filtering glasses) condition or “placebo” (glasses without filtering properties) condition. Patients were continually monitored by wristwatch actigraphy, kept their sleep diaries and completed a standard questionnaire battery at admission and after the end of the program. Statistical analyses showed a greater reduction of BAI score in “active” (4.33 ± 4.58) versus “placebo” (−0.92 ± 3.68) groups of patients [F = 6.389, p = .019, Cohen’s d = 1.26] and significant prolongation of subjective total sleep time in “active” (−36.88 ± 48.68 min.) versus “placebo” (7.04 ± 47.50 min.) [F = 8.56, p < .01, d = 0.91] group. When pre- and post-treatment results were compared in both groups separately, using paired-samples t-tests, significant differences were observed also in the active group for BDI-II score (t = 3.66, p = .003, Cohen’s d = 0.95) and HAS score (t = 2.90, p = .012, Cohen’s d = 0.75). No significant differences were found in the placebo group. In active group, there was also a significant reduction of subjective sleep latency (t = 2.65, p = .021, d = 0.73) and an increase of subjective total sleep time (t = −2.73, p = .018, d = −0.76) without change in objective sleep duration which was significantly shortened in the placebo group. We provide further evidence that blocking short-wavelength light in the evening hours may be beneficial for patients suffering from insomnia.

3 December 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
DDDaniela Dudysová
Daniela Dudysová
KJKarolina Janků
Karolina Janků
MŠMichal Šmotek
Michal Šmotek
ESElizaveta Saifutdinova
Elizaveta Saifutdinova
JKJana Kopřivová
Jana Kopřivová
JHJiří Horáček
Jiří Horáček
Serotonergic agonist psilocybin is a psychedelic with antidepressant potential. Sleep may interact with psilocybin’s antidepressant properties like other antidepressant drugs via induction of neuroplasticity. The main aim of the study was to evaluate the effect of psilocybin on sleep architecture on the night after psilocybin administration. Regarding the potential antidepressant properties, we hypothesized that psilocybin, similar to other classical antidepressants, would reduce rapid eye movement (REM) sleep and prolong REM sleep latency. Moreover, we also hypothesized that psilocybin would promote slow-wave activity (SWA) expression in the first sleep cycle, a marker of sleep-related neuroplasticity. Twenty healthy volunteers (10 women, age 28–53) underwent two drug administration sessions, psilocybin or placebo, in a randomized, double-blinded design. Changes in sleep macrostructure, SWA during the first sleep cycle, whole night EEG spectral power across frequencies in non-rapid eye movement (NREM) and REM sleep, and changes in subjective sleep measures were analyzed. The results revealed prolonged REM sleep latency after psilocybin administration and a trend toward a decrease in overall REM sleep duration. No changes in NREM sleep were observed. Psilocybin did not affect EEG power spectra in NREM or REM sleep when examined across the whole night. However, psilocybin suppressed SWA in the first sleep cycle. No evidence was found for sleep-related neuroplasticity, however, a different dosage, timing, effect on homeostatic regulation of sleep, or other mechanisms related to antidepressant effects may play a role. Overall, this study suggests that potential antidepressant properties of psilocybin might be related to changes in sleep.